<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160419</url>
  </required_header>
  <id_info>
    <org_study_id>NEO-FLOT</org_study_id>
    <secondary_id>EudraCT Nr.: 2008-007546-56</secondary_id>
    <nct_id>NCT01160419</nct_id>
  </id_info>
  <brief_title>Multicenter Study to Perioperative Chemotherapy for Resectable Adenocarcinoma in Gastric Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <brief_summary>
    <textblock>
      The rationale of the NEO-FLOT-trial consists of an intensification of the neoadjuvant&#xD;
      treatment.&#xD;
&#xD;
      This strategy is based upon the clear advantage of perioperative treatment and the fact, that&#xD;
      in former trials adjuvant treatment could only be given in half of the patients (Cunningham&#xD;
      2006, Boige 2007).&#xD;
&#xD;
      In this study neoadjuvant chemotherapy is applied during a period of 12 weeks with an interim&#xD;
      staging after 6 weeks.Due to the favourable efficacy and toxicity data the FLOT-regimen was&#xD;
      chosen for the neoadjuvant treatment consisting of oxaliplatin, docetaxel, folinic acid and&#xD;
      5-Fluorouracil (Al-Batran 2008).&#xD;
&#xD;
      Postoperative treatment according to the results of the MAGIC trail is not part of the trail&#xD;
      and is given at the responsibility of the participating centres.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Collection of the R0-Resection rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>after 6 cycles of biweekly FLOT chemotherapy and operation.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>FLOT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Docetaxel, Oxaliplatin, Folinic acid, 5-FU, q 2 weeks, application of 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel 50 mg/m2, 1-hour-Infusion, day 1</intervention_name>
    <description>50 mg/m2, 1-hour-Infusion, day 1</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin 85 mg/m², 2-hour-Infusion, day 1</intervention_name>
    <description>85 mg/m², 2-hour-Infusion, day 1</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic acid 200 mg/m², 1-2-hour-Infusion, day 1</intervention_name>
    <description>200 mg/m², 1-2-hour-Infusion, day 1</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU 2600 mg/m², 24-hour-Infusion, day 1</intervention_name>
    <description>2600 mg/m², 24-hour-Infusion, day 1</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically Confirmed Adenocarcinoma of the Gastroesophageal Junction (AEG I-III)&#xD;
             or Gastric Adenocarcinoma (every T, N+ or T3/T4, Nx, M0)&#xD;
&#xD;
          -  Written Informed Consent&#xD;
&#xD;
          -  Age ≥ 18 Years&#xD;
&#xD;
          -  Expected operability&#xD;
&#xD;
          -  ECOG ≤ 2&#xD;
&#xD;
          -  Exclusion of Peritoneal Metastasis&#xD;
&#xD;
          -  Adequate Hematological, Renal, Cardiac and Hepatic Function&#xD;
&#xD;
          -  Effective Contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior Chemotherapy or Radiotherapy of the Adenocarcinoma of the Gastroesophageal&#xD;
             Junction (AEG I-III) or Gastric Adenocarcinoma&#xD;
&#xD;
          -  Not Histologically Confirmed Primary Tumor&#xD;
&#xD;
          -  Distant Metastasis, Local Relapse&#xD;
&#xD;
          -  Known Hypersensitivity for 5-Fluorouracil, Leucovorin, Oxaliplatin or Docetaxel&#xD;
&#xD;
          -  Known Dihydropyrimidin-Dehydrogenase (DPD) - Deficiency&#xD;
&#xD;
          -  Peripheral Polyneuropathy ≥ Grade II (NCI-CTCAE, Version 3.0)&#xD;
&#xD;
          -  Myocardial Infarction in the last 3 Months, Cardiac Insufficiency Grade II-IV (NYHA)&#xD;
&#xD;
          -  Severe Comorbidity or Acute Infections&#xD;
&#xD;
          -  Pregnancy or Breast Feeding&#xD;
&#xD;
          -  Insufficient Contraception&#xD;
&#xD;
          -  Participation in another Clinical Trial (Simultaneously or 30 Days Prior to&#xD;
             Enrollment)&#xD;
&#xD;
          -  Malignancy &lt;5 years (except: Carcinoma In Situ of the Cervix Uteri or Adequately&#xD;
             Treated Basalioma of the Skin)&#xD;
&#xD;
          -  Lack of Legal Capacity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Munich, Klinikum Grosshadern</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>October 22, 2009</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>October 27, 2010</last_update_submitted>
  <last_update_submitted_qc>October 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. V. Heinemann</name_title>
    <organization>University of Munich - Klinikum Großhadern</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

